Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Amortizatization of Intangibles (2016 - 2025)

Historic Amortizatization of Intangibles for Adma Biologics (ADMA) over the last 13 years, with Q3 2025 value amounting to $170000.0.

  • Adma Biologics' Amortizatization of Intangibles fell 3253.97% to $170000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $739000.0, marking a year-over-year decrease of 4832.17%. This contributed to the annual value of $951000.0 for FY2024, which is 6333.85% down from last year.
  • Latest data reveals that Adma Biologics reported Amortizatization of Intangibles of $170000.0 as of Q3 2025, which was down 3253.97% from $160000.0 recorded in Q2 2025.
  • Adma Biologics' Amortizatization of Intangibles' 5-year high stood at $981066.0 during Q3 2022, with a 5-year trough of $160000.0 in Q2 2025.
  • For the 5-year period, Adma Biologics' Amortizatization of Intangibles averaged around $440210.5, with its median value being $464357.0 (2021).
  • Its Amortizatization of Intangibles has fluctuated over the past 5 years, first surged by 10186.92% in 2022, then tumbled by 6862.46% in 2024.
  • Over the past 5 years, Adma Biologics' Amortizatization of Intangibles (Quarter) stood at $502858.0 in 2021, then decreased by 1.79% to $493873.0 in 2022, then surged by 41.33% to $698000.0 in 2023, then crashed by 68.62% to $219000.0 in 2024, then fell by 22.37% to $170000.0 in 2025.
  • Its last three reported values are $170000.0 in Q3 2025, $160000.0 for Q2 2025, and $190000.0 during Q1 2025.